Dr Phillip Wong

Dr Phillip Wong graduated from the University of Melbourne and undertook training in endocrinology at the Royal North Shore Hospital (Sydney), St Vincent’s Hospital (Sydney) and Monash Health (Melbourne).

He obtained his PhD through the Hudson Institute where he investigated the pathophysiology of bone disease in patients with thalassaemia. Dr Wong has made important contributions to our understanding of the link between renal and bone disease in thalassaemia. His research has resulted in a change to the guidelines on the monitoring of renal and bone disease in thalassaemia.

Dr Wong was awarded the Bryan Hudson Award in 2014 from the Endocrine of Society of Australia for his PhD research. His work has been published in international journals and presented at national and international conferences.

In addition to his research role at the Hudson, Dr Wong sees patients through the metabolic bone clinic at Monash Health; and therefore allowing for the translation of research findings to clinical practice.

Recent Achievements: Amgen-GSK OA-ANZBMS Clinical Grant Program Award

Selected publications

  • Wong, P., Polkinghorne, Kerr, P.G., Doery, J.C.G., Gillespie, M.T., Larmour, I., Fuller, P.J., Bowden, D.K., Milat F. Deferasirox at Therapeutic Doses is Associated with Dose-Dependent Hypercalciuria – Accepted for publication in Bone 2016

  • Trinh A, Wong P, Fahey MC, Brown J, Churchyard A, Strauss BJ, Ebeling PR, Fuller PJ, Milat F. Musculoskeletal and endocrine health in adults with cerebral palsy: new opportunities for intervention. Journal of Clinical Endocrinology Metabolism 2016:jc20153888

  • Wong, P., Fuller, P.J., Gillespie, M.T., Kartsogiannis, V., Kerr, P.G., Doery, J.C., Paul, E., Bowden, D.K., Strauss, B.J., and Milat, F. (2014). Thalassemia bone disease: a 19-year longitudinal analysis. Journal of Bone and Mineral Research 29, 2468-2473.

  • Wong, P., Fuller, P.J., Gillespie, M.T., Kartsogiannis, V., Milat, F., Bowden, D.K., and Strauss, B.J. (2014). The effect of gonadal status on body composition and bone mineral density in transfusion-dependent thalassemia. Osteoporosis International 25, 597-604.

  • Wong, P., Fuller, P.J., Gillespie, M.T., Kartsogiannis, V., Strauss, B.J., Bowden, D., and Milat, F. (2013). Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporosis International 24, 1965-1971.

  • Milat, F., Wong, P., Fuller, P.J., Johnstone, L., Kerr, P.G., Doery, J.C.G., Strauss, B.J., and Bowden, D.K. (2012). A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. Journal of Bone and Mineral Research 27, 219-222.